Immunotherapy plus chemo before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (Retlirafusp Alfa) combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow surgery, and is for patients with specific types of HER2-negative or low-HER2 cancer and a PD-L1 CPS score of 1 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stomach or gastroesophageal junction cancer confirmed by a biopsy
- Your cancer must be considered potentially removable by surgery, with certain spread patterns allowed
- You must have HER2-negative, low, or intermediate levels, and a PD-L1 CPS score of 1 or higher
- You must be between 18 and 75 years old
- You must be in good enough health to have a performance status of 0 or 1 (able to do daily activities)
- You cannot have had any prior chemotherapy or targeted therapy for advanced or metastatic disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This trial tests a new drug called retlirafusp alfa combined with chemotherapy as a treatment before and after surgery for a specific type of stomach cancer. It aims to see if this combination is safe and effective for patients whose cancer has a high level of a certain protein (CPS > 5) and is not driven by HER2.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.